Nuwellis terminated its REVERSE‑HF randomized trial comparing ultrafiltration with IV loop diuretics in hospitalized heart ...

Stereotaxis announced that it entered into definitive agreements with investors to sell approximately $12.5 million in common stock.

NanoVibronix (Nasdaq:NAOV) today announced that it entered into a definitive agreement to sell up to $50 million in stock.

Exactech today announced it appointed Dr. Richard J. Friedman as chief medical officer, effective immediately.

UroMems received FDA investigational device exemption (IDE) approval to begin a first-of-its-kind trial for its smart implant.